Navigation Links
BioLineRx Presents Data From Successful Phase I Trial for BL-1020,in Schizophrenia at American Psychiatric Association Conference

SAN DIEGO--(BUSINESS WIRE)--May 22, 2007 - BioLineRx Ltd. (TASE:BLRX), Israel's leading drug development company, reported today data from its Phase I trial of BL-1020, the first GABA enhanced antipsychotic clinical candidate for the treatment of schizophrenia. The trial demonstrated that the compound was well tolerated and demonstrated biochemical evidence of dopamine blockade which is indicative of efficacy. BioLineRx presented the data in a poster (Abstract 235 XX) at the 2007 American Psychiatric Association (APA) Annual Meeting, which is being held May 19-24 in San-Diego, CA. A Phase II clinical trial for BL-1020 to determine the maximum tolerated dose in schizophrenic patients is expected to begin in the end of June, 2007.

"We are pleased to be presenting these promising results for BL-1020 at the APA Annual Meeting and look forward to the imminent initiation of the Phase II trial for this compound," commented Morris C. Laster, M.D., chief executive officer of BioLineRx.

The results of this trial were as follows:

1. BL-1020 demonstrated dopamine blockade by dose dependant elevation in serum prolactin levels which serves as a surrogate marker for dopamine antagonism. Dopamine hyperactivity is implicated in schizophrenia, and is the mechanism of action for various antipsychotic drugs.

2. In this trial BL-1020 appeared to be protective against extrapyramidal symptoms, a severe side effect of many antipsychotic medications. BL-1020 was extremely well tolerated in that no ECG psychiatric or neurological abnormalities were seen at any of the doses tested.

About the BL-1020 Phase I Clinical Trial

The Phase 1 trial of BL-1020 was a randomized, double blind, placebo-controlled, dose-escalation, single center study in healthy adult males (ages 21-45). The primary objective was to evaluate the safety and tolerability of escalating doses of BL-1020. The secondary objectives were to
'"/>




Page: 1 2 3 4

Related medicine technology :

1. BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming Clinical Conferences
2. BioLineRx Presents Data on BL-1040 at Cardiovascular Revascularization Therapies Conference Demonstrating Potential to Reduce Deterioration of Infarcted Heart Tissue and Maintain Functionality
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
5. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
6. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
7. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
8. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
9. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
10. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
11. Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its Ghrelin Antagonist Program at the American Diabetes Associations Annual Meeting
Post Your Comments:
(Date:11/22/2014)... 21 de noviembre de 2014  BioClinica®, Inc., ... externalizados y tecnologías eClinical, ha indicado un aumento ... inteligente, para el seguimiento basado en el riesgo ... el concepto del seguimiento basado en el riesgo ... visitas de seguimiento o cambio de los métodos ...
(Date:11/22/2014)... DUBLIN , Nov. 21, 2014 Research ... "China Recombinant Protein Drug Industry Report, 2014-2017" report ... The Chinese recombinant protein drug market ... demand rigidity, consumption ability and the like. During 2005-2013, ... hospitals grew at a CAGR of 19.1%, and it ...
(Date:11/21/2014)...  Tandem Diabetes Care ® , Inc. (NASDAQ: ... and manufacturer of the t:slim ® Insulin ... non-profit dedicated to improving diabetes therapy management by ... diabetes data accessibility. This partnership will enable users ... development, to download and access data from their ...
Breaking Medicine Technology:El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3China Recombinant Protein Drug Industry Report, 2014-2017 2China Recombinant Protein Drug Industry Report, 2014-2017 3Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 2Tandem Diabetes Care Announces Partnership with Tidepool to Further Expand Access to Diabetes Device Data 3
... 14, 2011 Reportlinker.com announces that a new ... Test-Volume-Sales-Forecasts-and-Supplier-Shares-by-Country.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_Diagnostic title=,The 2011 Prostatic ... Test Volume, Sales ... Acid Phosphatase Testing Market: US, Europe, Japan ...
... Nov. 14, 2011 Reportlinker.com announces that a ... catalogue: Smart Infusion Pumps ... is one of the most common therapeutic procedures ... to receive. Yet the lack of standardization among ...
Cached Medicine Technology:The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 2The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 3The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 4The 2011 Prostatic Acid Phosphatase Testing Market: US, Europe, Japan 5Smart Infusion Pumps 2Smart Infusion Pumps 3
(Date:11/24/2014)... Volpara Solutions announced today that it ... Annual Meeting of the Radiology Society of North ... 1752 – South Hall). Volpara Solutions will showcase ... of its innovative suite of quantitative breast imaging ... measurements of volumetric density, patient-specific dose, breast compression ...
(Date:11/24/2014)... Recently, SweetDressy.com, a well-known dress supplier and leader in ... Evening Dresses. All these fresh items are offered at ... the special offer is valid until Dec. 20, 2014. ... been working well in the fashion industry for years. ... new dresses may be the best products for many ...
(Date:11/24/2014)... 2014 SafeHandles™ announced that they will ... Ed Begley Jr, airing via Discovery Channel. Dates and ... a passive, non-invasive, replaceable, and affordable germ protective device. ... shrinkable sleeves and adhesives to promote hand hygiene in ... core of SafeHandles is the desire to make a ...
(Date:11/23/2014)... The clinical trial report, "Aspergillosis ... on the Aspergillosis clinical trial scenario. This report ... clinical trials on Aspergillosis. It includes an overview ... as per the site of trial conduction across ... of disease clinical trials by their phase, trial ...
(Date:11/23/2014)... Pro Ace Care, a renowned Vancouver hot water tank company, ... 8 year warranty on its selected hot water tanks. As ... to the impending winter season, it was important for Pro ... that the company provides. As a result, Pro Ace will ... Bradford hot water tanks. , “Every installer who works ...
Breaking Medicine News(10 mins):Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 2Health News:Volpara Solutions to Launch VolparaAnalytics 1.2 at RSNA 3Health News:SweetDressy.com Unveiled A New Selection Of Evening Dresses 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 2Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 3Health News:Aspergillosis Pipeline and Clinical Trials Market (Compnies and Drugs) Review H2 2014 Report at ReportsnReports.com 4Health News:Pro Ace Care Now Gives 8 Year Guarantee on Selected Vancouver Hot Water Tanks 2
... people who are unlikely to incur high medical expenses. ... families, finds a study of Massachusetts families from Children,s ... Care and Prevention (DACP). The study appears in the ... The researchers, led by Alison Galbraith, MD, MPH, and ...
... survive severe injuries on battlefields such as those in ... infections of their wounds with multidrug resistant bacteria. The ... Staphylococcus aureus (MRSA), Acinetobacter baumannii , ... coli . , Dr Clinton K. Murray, from Brooke ...
... to create open access to information that will enhance ... ORLANDO, Fla., March 29 /PRNewswire/ -- ... GE Healthcare,s Cardiovascular Ultrasound unit announced a formal affiliation ... an integrated solution aimed at improving workflow for echocardiography ...
... allergen breathed in by a person with asthma triggers a ... events to prompt an allergic reaction, said a consortium of ... in Houston in a report that appears online today in ... activates interleukin 25, a key mediator of the allergic response ...
... Relaxin cuts shortness of breath and trimmed hospital stays, phase ... The hormone relaxin reduces shortness of breath and cardiovascular death ... pressure, according to a phase 2 trial conducted in eight ... a few hours of arriving at a hospital, were randomly ...
... Doctor urges first responders to clean equipment regularly ... News) -- One in three stethoscopes used by ... methicillin-resistant Staphylococcus aureus (MRSA) bacteria, a new study ... and Dentistry of New Jersey swabbed 50 stethoscopes ...
Cached Medicine News:Health News:Low-income families with sick children often enrolled in high-deductible health care plans 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 2Health News:ProSolv CardioVascular and GE Healthcare Ultrasound Division Announce Affiliation 3Health News:Hormone Reduces Mortality in Heart Patients With High BP 2Health News:Third of EMS Stethoscopes Carry MRSA Bacterium 2
Inquire...
Inquire...
Inquire...
... a range of 18 Ophthalmic frames ... and producted to the very hightest ... super lightweight Titanium and Beta Titanium ... host of beautifully formed and innovative ...
Medicine Products: